Navigation Links
Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
Date:1/12/2009

CAMBRIDGE, Mass., Jan. 12 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced that it has initiated a proof-of-concept study of IDX184, a liver-targeted nucleotide prodrug candidate for the treatment of HCV under an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA). The study is evaluating IDX184 in treatment-naive hepatitis C genotype-1 infected patients.

"We are very pleased with the progress that we have made in our hepatitis C discovery program in 2008, having successfully advanced IDX184 from IND to a proof-of-concept study, while simultaneously advancing two additional HCV discovery programs into IND-enabling preclinical studies," said Jean-Pierre Sommadossi, Ph.D., chief executive officer of Idenix. "As we work to finalize a partnership for our lead HIV drug candidate, our goal in 2009 is to become the first biopharmaceutical company with innovative drugs from three major classes of direct-acting hepatitis C antivirals in clinical development."

The proof-of-concept trial in HCV-infected patients is being conducted at multiple centers around the world. The trial design is a phase I/II, double-blind, placebo-controlled, dose-escalation study to evaluate the safety and antiviral activity of IDX184 in treatment-naive adult patients infected with chronic hepatitis C. The study will evaluate four doses of IDX184, ranging from 25 to 100 mg once-per-day, administered for three days. Each cohort of the study will evaluate ten patients randomized eight to IDX184 and two to placebo.

About IDX184

IDX184 is a once-daily, oral nucleotide prodrug candidate based on Idenix's proprietary li
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
2. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
5. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
6. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
7. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
8. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 ResMed (NYSE: RMD ... action against Chinese medical device manufacturer BMC Medical Co., Ltd. ... that BMC,s masks listed below infringe ResMed,s patents, and entered ... masks in the United States : ... mask , Willow nasal pillows mask , iVolve ...
(Date:12/24/2014)... , Dec. 23, 2014  The American ... blood pressure target for people with diabetes and ... or high doses of statins, in keeping with ... enacted by the American College of Cardiology (ACC) ... reflected in the most recent changes to the ...
(Date:12/22/2014)... N.J. , Dec. 22, 2014  CytoSorbents ... marketing its CytoSorb® blood purification technology to help ... patients in 28 countries worldwide, today announced the ... , MD, FACS, as its Senior Vice President ... Dr. Di Russo is ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... 7, 2011  Tethys Bioscience has entered into an agreement ... employers measurably flatten the trajectory of their healthcare trends ... their employee populations. The agreement allows ACAP Health to ... as a component of its disease intervention programs. The ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... of the granting of a European patent with broad ... diketopiperazine which is the active ingredient of Ampion™.  The ...
Cached Medicine Technology:Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 3Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™ 2
(Date:12/25/2014)... 24, 2014 (HealthDay News) -- Among early stage breast ... than half of one percent will eventually develop leukemia ... reveals. The finding comes from a review of ... and 2007, and it suggests that the risk for ... experts had previously thought. "The frequency of bone ...
(Date:12/25/2014)... December 25, 2014 AngelWeddingDress.com tries its ... the online realm. Today, the business has introduced its ... site-wide prom dress promotion. , The new prom outfits ... and every dress lover. They are specially designed for ... prom dresses should visit its website before Jan. ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as part ... mobile applications on the iOS, Android, and Windows markets. Andrew ... the app review and shared with viewers how this is ... old saying goes, “A picture says a thousand words.” It’s ... a single image, because each picture holds a unique and ...
(Date:12/25/2014)... Newton, North Carolina (PRWEB) December 25, 2014 ... a North Carolina Retirement Community, recently showed their ... and girls of the Catawba County Parenting Network- ... meal, the 10 children gathered around the largest ... community to open presents purchased by residents of ...
(Date:12/25/2014)... AZ (PRWEB) December 25, 2014 Parker ... to outstanding customer service and affordable quality regarding heating, ... area announces recognition in 2014 by the “Queen of ... Sons has earned an impressive reputation over the years ... on a wide range of contractor services for both ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3
... good for heart health, at least among men, a ... researcher Robert Gramling, M.D., D.Sc., found that men who ... actually experienced a three times lower incidence of death ... not support the same conclusion among women. One possible ...
... Australian first, scientists at Sydney,s Centenary Institute have mapped ... has the potential to turn the way we discover ... time for new treatments. , "These membrane proteins are ... an increased,understanding of them is vital for future drug ...
... Theoretical Bioinformatics at the German Cancer Research Center (Deutsches ... how cells decide whether or not to migrate. Using ... molecular targets within a cell that have to be ... direction. This method may help to develop new treatments ...
... YORK and PARSIPPANY, N.J., July 14 Healthfirst ... a free online service,for electronic claims submissions. This ... medical providers to do business with the health ... faster exchange of,information, higher acceptance rates and quicker ...
... announced the appointment of Gregory Ciottone,MD to the position of Chief ... ... Company., LONGMONT, Colo., July 14 ... Ciottone, MD,to the position of Chief Medical Officer. Dr. Ciottone will ...
... Combat Lifesaver ... ... the summer of 2005, the,U.S. Army approached Recon Mountaineer(R) LLC ... the Combat Lifesaver program, and,at gaining their approval, the TC3(R) ...
Cached Medicine News:Health News:Positive thinking is prescription for the heart 2Health News:Discovery first step to new therapies 2Health News:Cellular decision on the computer 2Health News:Healthfirst and MD On-Line Partner to Streamline Claims Processing 2Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 2Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 3Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 4Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 5Health News:Creator of Recon Moutaineer's Tactical Combat Casualty Care Bag Praises Combat Lifesavers 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: